Cargando…
Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin
Multiple sclerosis (MS) is a common autoimmune disease of the central nervous system, causing neurological disability in young adults. A growing understanding of its immunopathogenesis has led to an expanding array of therapies. Notable new advances in disease-modifying therapies for relapsing forms...
Autores principales: | Demas, Alexis, Cochin, Jean-Philippe, Hardy, Clémence, Vaschalde, Yvan, Bourre, Bertrand, Labauge, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229143/ https://www.ncbi.nlm.nih.gov/pubmed/31858407 http://dx.doi.org/10.1007/s40120-019-00175-2 |
Ejemplares similares
-
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016) -
(1)H‐(31)P magnetic resonance spectroscopy: effect of biotin in multiple sclerosis
por: Guillevin, Carole, et al.
Publicado: (2019) -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021) -
A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis
por: Lebrun, Christine, et al.
Publicado: (2017) -
Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)